Anavex Life Sciences Corp. (AVXL)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
AVXL Insider Trading Activity
AVXL Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $32,919 | 2 | 67 |
Sells | $374,972 | 1 | 33 |
Related Transactions
| Thomas Steffen | director | 1 | $22,600 | 0 | $0 | $22,600 |
| Donhauser Peter D.O. | director | 1 | $10,319 | 0 | $0 | $10,319 |
| MISSLING CHRISTOPHER U | President and CEO | 0 | $0 | 1 | $374,972 | $-374,972 |
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Insider Activity of Anavex Life Sciences Corp.
Over the last 12 months, insiders at Anavex Life Sciences Corp. have bought $32,919 and sold $374,972 worth of Anavex Life Sciences Corp. stock.
On average, over the past 5 years, insiders at Anavex Life Sciences Corp. have bought $19,536 and sold $2.45M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Thomas Steffen (director) — $22,600. Donhauser Peter D.O. (director) — $10,319.
The last purchase of 2,835 shares for transaction amount of $10,319 was made by Donhauser Peter D.O. (director) on 2024‑06‑14.
List of Insider Buy and Sell Transactions, Anavex Life Sciences Corp.
| 2024-06-14 | Donhauser Peter D.O. | director | 2,835 0.0033% | $3.64 | $10,319 | +81.43% | ||
| 2024-05-15 | Thomas Steffen | director | 5,000 0.0059% | $4.52 | $22,600 | +43.76% | ||
| 2024-03-28 | Sale | MISSLING CHRISTOPHER U | President and CEO | 73,380 0.0911% | $5.11 | $374,972 | +18.27% | |
| 2023-06-28 | Sale | MISSLING CHRISTOPHER U | President and CEO | 268,000 0.3424% | $7.98 | $2.14M | -24.69% | |
| 2022-05-25 | Sale | Skarpelos Athanasios | 50,000 0.0643% | $9.06 | $453,000 | +8.46% | ||
| 2021-06-29 | Sale | MISSLING CHRISTOPHER U | President and CEO | 51,620 0.0805% | $26.00 | $1.34M | -28.27% | |
| 2021-06-29 | Sale | Boenisch Sandra | PFO and Treasurer | 166,696 0.2651% | $26.53 | $4.42M | -28.27% | |
| 2021-05-21 | Sale | FAVUS ELLIOT | director | 145,000 0.2057% | $11.70 | $1.7M | +49.44% | |
| 2021-05-17 | Donhauser Peter D.O. | director | 1,000 0.0014% | $10.93 | $10,930 | +54.43% | ||
| 2021-02-24 | Sale | FAVUS ELLIOT | director | 145,500 0.2172% | $12.66 | $1.84M | +40.94% | |
| 2021-02-19 | Donhauser Peter D.O. | director | 1,165 0.0017% | $12.67 | $14,760 | +38.92% | ||
| 2018-03-07 | MISSLING CHRISTOPHER U | President and CEO | 1,360 0.0031% | $2.92 | $3,971 | -13.15% | ||
| 2018-03-06 | MISSLING CHRISTOPHER U | President and CEO | 1,450 0.003% | $2.73 | $3,959 | -14.33% | ||
| 2018-03-05 | MISSLING CHRISTOPHER U | President and CEO | 1,500 0.0034% | $2.63 | $3,945 | -4.20% | ||
| 2018-03-02 | MISSLING CHRISTOPHER U | Director, President & CEO | 1,650 0.0034% | $2.41 | $3,977 | -3.85% | ||
| 2017-10-25 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0009% | $4.39 | $1,646 | -36.81% | ||
| 2017-10-24 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0009% | $4.92 | $1,845 | -41.40% | ||
| 2017-10-19 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0008% | $4.49 | $1,684 | -40.47% | ||
| 2017-10-17 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0009% | $4.27 | $1,601 | -34.35% | ||
| 2017-10-13 | MISSLING CHRISTOPHER U | President and CEO | 750 0.0017% | $4.22 | $3,165 | -34.58% |
Insider Historical Profitability
| MISSLING CHRISTOPHER U | President and CEO | 1250210 1.4697% | $12.18M | 39 | 3 | +42.64% |
| Thomas Steffen | director | 5000 0.0059% | $48,700.00 | 1 | 0 | |
| Donhauser Peter D.O. | director | 5000 0.0059% | $48,700.00 | 3 | 0 | +46.67% |
| Skarpelos Athanasios | 1306458 1.5358% | $12.72M | 1 | 6 | ||
| Lalach Harvey | President COO Secretary | 550000 0.6466% | $5.36M | 0 | 8 | |
| Boenisch Sandra | PFO and Treasurer | 22963 0.027% | $223,659.62 | 0 | 1 | |
| Wu Pei Ru | COO | 0 0% | $0 | 0 | 1 | |
| Wu Yang | President & CEO | 0 0% | $0 | 0 | 1 | |
| FAVUS ELLIOT | director | 0 0% | $0 | 0 | 2 |
Historical Insider Profitability vs. Competitors
$3,596,906 | 112 | 13.42% | $661.99M | |
$7,929,017 | 58 | 21.56% | $764.46M | |
$571,084,134 | 44 | 4.33% | $946.22M | |
Anavex Life Sciences Corp. (AVXL) | $97,176 | 41 | 42.84% | $828.53M |
$28,907,358 | 35 | 41.41% | $930.1M | |
$61,752,931 | 34 | 14.31% | $894.39M | |
$149,456,352 | 27 | -8.77% | $727.09M | |
$22,007,592 | 17 | -0.43% | $638.21M | |
$104,137,421 | 15 | 21.28% | $898.89M | |
$109,488,423 | 15 | 56.69% | $698.14M | |
$4,210,269 | 14 | -15.87% | $692.64M | |
$103,194,328 | 13 | 9.02% | $834.15M | |
$50,317,062 | 13 | -3.69% | $885.02M | |
$278,247,340 | 12 | 58.08% | $950.4M | |
$9,976,473 | 12 | 29.52% | $748.46M | |
$20,499,451 | 9 | 71.54% | $815.17M | |
$49,165,200 | 7 | 12.92% | $833.3M | |
$46,235,722 | 6 | -31.77% | $931.65M | |
$504,640 | 1 | 16.84% | $791.05M |
AVXL Institutional Investors: Active Positions
| Increased Positions | 97 | +62.18% | 5M | +18.01% |
| Decreased Positions | 62 | -39.74% | 2M | -8.46% |
| New Positions | 48 | New | 2M | New |
| Sold Out Positions | 21 | Sold Out | 642,330 | Sold Out |
| Total Postitions | 191 | +22.44% | 30M | +9.55% |
AVXL Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $61,786.00 | 7.71% | 6.55M | -188,647 | -2.8% | 2024-12-31 |
| Vanguard Group Inc | $44,137.00 | 5.51% | 4.68M | -59,727 | -1.26% | 2024-12-31 |
| State Street Corp | $22,744.00 | 2.84% | 2.41M | -654,018 | -21.33% | 2024-12-31 |
| Geode Capital Management, Llc | $17,681.00 | 2.21% | 1.87M | -8,277 | -0.44% | 2024-12-31 |
| Susquehanna International Group, Llp | $10,701.00 | 1.34% | 1.13M | +896,321 | +375.95% | 2024-12-31 |
| Nwam Llc | $8,610.00 | 1.07% | 913,051 | +2,575 | +0.28% | 2024-12-31 |
| Morgan Stanley | $8,526.00 | 1.06% | 904,159 | +185,604 | +25.83% | 2024-12-31 |
| Two Sigma Investments, Lp | $7,326.00 | 0.91% | 776,901 | -53,723 | -6.47% | 2024-12-31 |
| Northern Trust Corp | $6,666.00 | 0.83% | 706,901 | +10,938 | +1.57% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $6,386.00 | 0.8% | 677,215 | +11,239 | +1.69% | 2024-12-31 |